Doorgaan naar inhoud
Qualified safety assessorsUK · EU · USA
Get a quote
  1. Home
  2. BLOGS
  3. MoCRA Serious Adverse Event Reporting: What Counts as Serious, the 15 Business Day Clock and the Records FDA Can Inspect

MoCRA Serious Adverse Event Reporting: What Counts as Serious, the 15 Business Day Clock and the Records FDA Can Inspect

A working guide to the US reporting duty: the statutory list of serious outcomes, ten real-world complaints sorted, the deadline counted out on a calendar, the FDA submission routes and what your complaint file has to show

S Syed Muhammad Shamuel SheesFounder & Lead Compliance Consultant
14 min read
Reviewed by Phoenix Cosmetic Safety · Nov 22, 2026
A gloved dermatologist examining a patient's skin for a reaction.

The short answer

Under MoCRA, the responsible person named on a US cosmetic label must send FDA any report it receives of a serious adverse event linked to use of the product in the United States, with a copy of the label, no later than 15 business days after receiving it. Serious is defined by a fixed list in the statute: death, a life-threatening experience, inpatient hospitalisation, persistent or significant disability, congenital anomaly, infection, or significant disfigurement such as persistent rashes, burns or significant hair loss, plus any event needing medical intervention to prevent one of these. New and material medical information received within a year follows within another 15 business days. Records of every adverse event are kept for 6 years, or 3 for a qualifying small business.

Key takeaways

  • The duty belongs to whoever is named on the US label as manufacturer, packer or distributor. It is not an appointment, and the small business exemption does not remove it.
  • Serious is a statutory checklist. Infection and significant disfigurement, including persistent rashes, burns and significant hair loss, make many events reportable with no hospital involved.
  • The report, with a copy of the label, is due no later than 15 business days after you receive the complaint, not after you finish investigating.
  • New and material medical information received within a year of the first report must be sent within another 15 business days.
  • Every adverse event linked to US use is recorded and kept for 6 years, or 3 for a qualifying small business that makes none of the higher-risk product types.
  • FDA accepts reports by gateway, through the Safety Reporting Portal or on Form FDA 3500A. Request your portal account before you need it.
  • A report is not an admission that your product caused the event. Failing to report is a prohibited act.

A customer emails on a Friday evening. She used your new exfoliating serum, came up in a rash, and three weeks later it still hasn't gone. Customer service apologises, sends a refund and closes the ticket. Under US law that may have been a serious adverse event, and the 15 business day deadline for telling FDA started the moment the email landed, not when anyone realised what it was.

That is what makes MoCRA serious adverse event reporting different from the rest of the Modernization of Cosmetics Regulation Act. You choose when to list a product or register a facility. You don't choose when a complaint arrives. This guide works from the statute itself, section 605 of the Federal Food, Drug, and Cosmetic Act, and from FDA's current reporting instructions. It covers what "serious" means, who has to report, how to count the days, where the report goes and what your records must show. Listing and registration are covered separately in our guide to MoCRA product listing and facility registration.

What counts as a serious adverse event under MoCRA

Start with two definitions in section 604. An adverse event is "any health-related event associated with the use of a cosmetic product that is adverse". That is deliberately wide. It doesn't require proof that your product caused anything, only that the event is associated with its use.

A serious adverse event is an adverse event that results in one of these outcomes:

  • death
  • a life-threatening experience
  • inpatient hospitalisation
  • a persistent or significant disability or incapacity
  • a congenital anomaly or birth defect
  • an infection
  • significant disfigurement, which the statute says includes serious and persistent rashes, second- or third-degree burns, significant hair loss, or persistent or significant alteration of appearance, other than as intended, under conditions of use that are customary or usual

It also covers an event that, based on reasonable medical judgment, requires medical or surgical intervention to prevent one of those outcomes.

Two parts of that list do most of the work for cosmetics. The first is infection. An eye infection after mascara is serious even if it clears up in a week with drops. The second is significant disfigurement, because it pulls in the complaints cosmetic brands actually receive: rashes that persist, burns from hair removal or chemical peels, and hair loss after dyes, relaxers or straighteners. None of those needs a hospital. If your team only escalates when a customer mentions hospital or the emergency room, it will miss most of what the statute is aiming at.

The words "other than as intended" matter too. A self-tanner that turns skin brown, or a hair colour that changes the shade of hair, is altering appearance as it is meant to. That is not disfigurement. Patchy staining that won't wash off, or hair that breaks off at the root, is a different story.

Ten complaints, sorted

The easiest way to train a team is with real examples. Here is how we would sort ten complaints of the kind that reach a small brand in a normal month. The point is not to make a clinical diagnosis at the help desk. It is to spot anything that touches the list and send it to the person who owns the decision.

What the customer told youAdverse event?Serious?Why
Face serum: redness and tingling for a day, gone after she stopped using itYesNoA short-lived reaction with none of the listed outcomes. Record it and close it
Face serum: a rash that has lasted three weeks and spread to her neckYesYesA serious and persistent rash is named in the disfigurement limb
Hair relaxer: patches of hair loss a week after useYesYesSignificant hair loss is named in the disfigurement limb
Depilatory cream: blistering burn, seen at an urgent care clinicYesYesA second-degree burn is named in the disfigurement limb
Mascara: eye infection treated with antibiotic dropsYesYesInfection is a listed outcome in its own right
Body lotion: hives and swollen lips, went to the emergency room, treated and sent homeYesTreat as yesNot inpatient hospitalisation, but a doctor may judge the treatment prevented a life-threatening outcome. Escalate and ask for the medical details
Semi-permanent hair colour: the shade came out darker than the boxNoNoA change of appearance that the product is meant to cause is excluded by the words 'other than as intended'. Log it as a quality complaint
Shampoo: the bottle smells sour, nobody has used itNoNoNo health event. Handle it as a product quality complaint and check the batch
Lip balm bought in London: swelling that lasted a fortnightNot under MoCRANot under MoCRAThe US duty covers use in the United States. Assess it under the GB rules instead
Influencer comment: 'this cream gave me a rash'PossiblyUnknownContact the person, log what you learn and assess it. A vague report still deserves a record

Two habits make this table work in practice. When in doubt, escalate and assess, because a report you didn't need to make costs an hour and a missed report is a breach. And ask the customer for the facts that decide the question: how long the reaction lasted, whether a doctor was involved, what treatment was given, and whether they still have the product and its batch code. Ask early, because those questions take days to answer and the clock is already running.

Who holds the duty: whoever is named on the US label

The duty sits with the responsible person, defined in section 604 as "the manufacturer, packer, or distributor of a cosmetic product whose name appears on the label". It is not an appointment, as it is in the EU and UK. You find the responsible person by reading the pack.

In practice that gives three common set-ups:

  • Your brand is named on the label. The duty is yours, wherever your company is based. A UK or EU brand selling into the US through its own website or Amazon is usually in this position.
  • A US distributor is named, for example "Distributed by" followed by its details. The distributor is the responsible person. Your contract should say how complaints that reach you first get to them the same day.
  • A contract manufacturer or private-label supplier is named. Then it is them. If your brand is named instead, as is usual with private label, it is you, even though you never touched the formula. Our article on private and white label compliance covers who carries what.

Section 609(a) adds a label requirement that makes the system work: every cosmetic product must carry a domestic address, a domestic telephone number, or electronic contact information, which may include a website, through which the responsible person can receive adverse event reports. That requirement took effect on 29 December 2024, two years after MoCRA was enacted. Section 605 then says the responsible person receives reports through that contact. If the contact on your pack is a web form that feeds an inbox nobody checks at weekends, the gap is yours to fix. A US cosmetic label review will check the contact line along with the rest of the label.

One trap catches small brands. MoCRA exempts qualifying small businesses from facility registration, product listing and good manufacturing practice rules under section 612, but that exemption doesn't touch adverse event reporting. Every responsible person reports, whatever its size. Small businesses only get a shorter record retention period, covered below.

The 15 business day clock, counted out

Section 605(b)(1) says the responsible person must submit the report, together with a copy of the label on or within the retail packaging, "no later than 15 business days after the report is received by the responsible person". Three features of that sentence drive everything else.

  • It runs from receipt. Not from the end of your investigation, not from the date you got photos. You can and should keep investigating after you report.
  • It is measured in business days. The statute doesn't define them. Weekends clearly don't count. Whether US federal holidays count is not spelled out, so we plan on the earlier date and treat holidays as a bonus, never as a cushion.
  • It starts with whoever receives the report for you. We treat a complaint that reaches your customer service agency, your Amazon seller messages or a US distributor's help line as received by you on that day, because arguing otherwise after the deadline is not a good position.

Here is what the clock looks like on a real calendar over the coming holiday season:

Report received15 business days counting every weekdaySkipping US federal holidaysCalendar days you actually have
Monday 23 November 2026Monday 14 December 2026Tuesday 15 December 2026 (Thanksgiving is 26 November)21 or 22
Friday 18 December 2026Friday 8 January 2027Tuesday 12 January 2027 (Christmas Day and New Year's Day)21 or 25
New medical information on Tuesday 2 February 2027 about the 23 November reportTuesday 23 February 2027Wednesday 24 February 2027 (Presidents' Day is 15 February)21 or 22

The second duty is easy to forget. Section 605(b)(2) requires you to send FDA any new and material medical information about a reported event that you receive within one year of the initial report, again no later than 15 business days after you receive it. A dermatologist's letter arriving two months later, a positive patch test, or news that the customer was admitted to hospital after all would all qualify. Diarise the one-year window when you submit the first report.

FDA has also been asked by the statute to build systems for submitting a single consolidated report when several people report the same event, for example a customer and her doctor. That helps with duplicates. It doesn't extend the deadline.

How to send the report to FDA

FDA's reporting page for industry, checked on 22 November 2026, offers three ways to file a mandatory serious adverse event report for a cosmetic:

  • Database-to-database transmission of the report in XML through FDA's Electronic Submissions Gateway. This suits companies already running safety databases. FDA asks you to contact AEMSeSub@fda.hhs.gov to set it up.
  • The Safety Reporting Portal, a web form for companies without that infrastructure. You need an account first, requested through the same address, and reports go in one at a time. There is no batch upload.
  • Paper Form FDA 3500A, the mandatory MedWatch form, completed and sent with one combined PDF of supporting material, such as label scans and photos of the reaction, by email to CosmeticAERS@fda.hhs.gov or by post to FDA's CDER Mail Center.

FDA prefers electronic filing. Our advice is simple: request the portal account now, before you have a report to send. Waiting for credentials is a bad use of a 15 day window.

Whichever route you use, include the copy of the label. It is in the statute, not just the form. Keep the label version that matches the batch the customer used, which is one more reason to keep dated artwork in your product file.

You will also see a new name on FDA's pages. In March 2026 FDA announced that it is merging its separate adverse event systems into a single FDA Adverse Event Monitoring System, AEMS, which replaces the old FAERS name. The legal duty hasn't changed, but older guides and bookmarks may point to retired pages. Non-serious events don't have to be reported, though FDA accepts them voluntarily on the same form.

Records: six years, or three for a qualifying small business

Section 605(e) is wider than the reporting duty. The responsible person must keep records related to each report of an adverse event associated with use of the product in the United States, serious or not, for 6 years. A responsible person that counts as a small business under section 612 keeps them for 3 years, but only if it doesn't make or process the higher-risk products listed there: products that regularly touch the mucous membrane of the eye, injected products, products for internal use, and products meant to alter appearance for more than 24 hours where removal by the consumer isn't part of normal use. A mascara brand, for example, is on the 6 year clock whatever its turnover.

The small business test itself is average gross annual US sales of cosmetic products under $1,000,000, adjusted for inflation, over the previous three years. If you are near the line, a small business exemption check is worth doing before you build the archive.

A useful record shows a decision being made, not just a complaint being logged. For each event we would keep:

  • the date and time of receipt, and the route it came by
  • the product, shade or variant, and the batch code
  • what the customer said, in their own words, with any photos
  • the outcomes reported and your assessment against each limb of the statutory list
  • the decision, serious or not, who made it and why
  • the date and reference of any FDA submission, and any follow-up sent within the year
  • what you did next: contact with the customer, batch review, changes to label or formula

FDA inspectors can ask for these records during an inspection under section 605(e)(2). Separately, section 610 lets FDA access and copy records where it reasonably believes a product is likely to be adulterated and presents a threat of serious adverse health consequences or death. Your adverse event log is one of the first things that will be asked for.

One more duty hides in section 605(f). If FDA has reasonable grounds to believe a fragrance or flavour ingredient caused or contributed to a serious adverse event, it can ask in writing for a list of the ingredients or categories of ingredients in that fragrance, and you have 30 days to provide it. If your fragrance house won't share its formula with you, agree now how they will answer FDA directly or through you.

The records also earn their keep commercially. Three similar complaints on one batch in a fortnight is the pattern that comes before a withdrawal decision. Our guide to cosmetic product recalls and withdrawals explains what to do once you see it.

What happens if you do not report

Failing to make a report required under section 605, or failing to keep the records, is a prohibited act under section 301(e) of the FD&C Act. So is refusing FDA access to those records. Falsifying a serious adverse event report is a separate prohibited act under section 301(ii). Those amendments took effect on 29 December 2023, one year after MoCRA was signed. Prohibited acts can lead to warning letters, import refusals and, in the worst cases, prosecution. And the breach is easy to prove after the event, because your own inbox shows when the complaint arrived.

The fear that holds brands back is usually liability. The statute deals with that directly. Section 605(h)(4) says a report submitted in compliance with the section "shall not be construed as an admission that the cosmetic product involved caused or contributed to the relevant adverse event". You may also attach a statement denying that the report is an admission of causation, and that statement goes with the report if it is ever released. Personal information is protected and must be redacted before any public disclosure. Reporting doesn't mean you agree the product was at fault. It means the event happened and reached you.

Insurance is the other half of that worry. A product liability policy that is in place before the first serious complaint is worth far more than one bought after it. We cover how that fits with your safety documents in our article on product liability insurance for cosmetics.

Selling in the UK and EU too: one register, three tests

Many of our clients sell the same product in the US, the UK and the EU. The mistake we see most is assuming the European cosmetovigilance process already covers the US. It doesn't, because the three systems ask different questions.

United States (MoCRA)European UnionGreat Britain
Legal basisFD&C Act sections 604 and 605 (21 U.S.C. 364 and 364a)Regulation (EC) No 1223/2009, Articles 2 and 23Regulation 1223/2009 as it applies in GB, Article 23
What triggers a reportSerious adverse event: death, life-threatening experience, inpatient hospitalisation, persistent or significant disability, congenital anomaly, infection, significant disfigurement, or intervention to prevent one of theseSerious undesirable effect: temporary or permanent functional incapacity, disability, hospitalisation, congenital anomalies, immediate vital risk or deathSame definition as the EU
Who reportsThe responsible person named on the labelThe Responsible Person and distributorsThe Responsible Person and distributors
To whomFDAThe competent authority of the member state where the effect occurredThe Secretary of State, in practice OPSS
DeadlineNo later than 15 business days after receiptWithout delay. Commission guidelines read this as 20 calendar daysWithout delay. OPSS guidance reads this as 30 calendar days
RecordsEvery adverse event, 6 years (3 for a qualifying small business)Undesirable effect data goes into the CPSR, and the product file is kept for 10 years after the last batchAs the EU

The persistent rash is the clearest example. Under the EU and GB definition, a rash that doesn't stop someone getting on with daily life is usually not a serious undesirable effect, and OPSS says as much in its guidance. Under MoCRA, a serious and persistent rash is named in the statute. The same complaint can be reportable in Texas and only loggable in Leeds.

The answer is one intake process and one complaint register, with three assessment branches. One register means nothing gets lost between teams. Separate branches mean each complaint is tested against the right definition and sent to the right authority, based on where the effect happened. Our guide to cosmetovigilance and serious undesirable effect reporting covers the UK and EU side in detail, and our side-by-side comparison of US, UK and EU cosmetics rules puts this duty next to the others.

Fewer complaints is the best outcome of all. Sensible pre-launch testing on a realistic panel cuts the number of strong reactions, as we explain in our article on cosmetic skin safety and patch testing. Clear directions for use cut the events that are really misuse. If you would rather not build any of this yourself, our comparison of MoCRA software and a compliance consultant sets out the options.

No process yet for a serious adverse event report?

Tell us whose name is on your US label, how complaints reach you today and which products you sell in the United States. We will confirm who holds the duty, set up an intake and triage routine against the statutory list, run the 15 business day clock for you and keep the adverse event file in the shape FDA expects to see at inspection.

Set up your reporting process Review your US label

Related reading

Myths we hear

  • Only hospital cases count as serious. The list includes infection and significant disfigurement, which the statute says covers serious and persistent rashes, second- or third-degree burns and significant hair loss. Most reportable cosmetic events never involve a hospital.
  • We can wait until we know whether the product caused it. The 15 business days run from receipt of the report. Causation is not a condition for reporting, and later medical information has its own follow-up deadline.
  • Small businesses are exempt from MoCRA. The small business exemption covers registration, listing and GMP only. Adverse event reporting applies to every responsible person, and small businesses only get a 3 year rather than 6 year record period.
  • Our EU cosmetovigilance process already covers the US. The definitions, the deadline, the recipient and the person with the duty all differ. A persistent rash can be reportable to FDA and still not be a serious undesirable effect in the EU or GB.
  • Reporting is admitting liability. Section 605 says a compliant report is not an admission that the product caused or contributed to the event, and you can attach a statement saying so.

What to do this week

  1. Read your US label and write down which company is named. That company is the responsible person, so confirm it knows.
  2. Check that the label carries a domestic address, domestic phone number or electronic contact for adverse events, and that someone reads it every working day.
  3. List every route a complaint can arrive by, including marketplace messages, social media, retailers, fulfilment partners and distributors, and give each an owner.
  4. Train front-line staff on the statutory list and the ten examples above, with one rule: anything that touches the list goes to the decision owner the same day.
  5. Name one person, plus a deputy, to own the 15 business day clock, and log the receipt date at the moment of escalation.
  6. Request a Safety Reporting Portal account through AEMSeSub@fda.hhs.gov now, and keep a blank Form FDA 3500A as a fallback.
  7. Open one complaint register for all adverse events, with your reasoning recorded for each decision, and set the retention period at 6 years unless you have confirmed you qualify for 3.
  8. Review the register every month for clusters by product and batch, and diarise the one-year follow-up window for every report you send.

Frequently asked questions

What is a serious adverse event under MoCRA?

An adverse event that results in death, a life-threatening experience, inpatient hospitalisation, a persistent or significant disability or incapacity, a congenital anomaly or birth defect, an infection, or significant disfigurement, or that needs medical or surgical intervention to prevent one of those outcomes. Disfigurement includes serious and persistent rashes, second- or third-degree burns and significant hair loss.

How long do I have to report a serious adverse event to FDA?

No later than 15 business days after the responsible person receives the report. Any new and material medical information received within one year of the first report must be sent within another 15 business days of receiving it. The clock runs from receipt, not from the end of your investigation.

Who has to report, the brand or the manufacturer?

The responsible person, meaning the manufacturer, packer or distributor whose name appears on the US label. If your brand is named, the duty is yours even if a contract manufacturer made the product. If a US distributor is named instead, the duty is theirs.

Does a rash count as serious?

A serious and persistent rash does. The statute names it in the significant disfigurement limb. A mild reaction that clears in a day or two is still an adverse event, so record it, but it is not serious unless another limb of the definition applies.

How do I submit the report?

FDA accepts electronic reports through the Electronic Submissions Gateway or the Safety Reporting Portal, and paper Form FDA 3500A by email to CosmeticAERS@fda.hhs.gov or by post. Portal accounts are requested through AEMSeSub@fda.hhs.gov. Include a copy of the product label with every report.

How long do I keep adverse event records?

Six years for each adverse event linked to use in the United States, serious or not. A qualifying small business keeps them for three years, unless it makes products such as eye-area cosmetics, injected products, products for internal use or long-lasting appearance-altering products.

Are small businesses exempt from adverse event reporting?

No. The MoCRA small business exemption covers facility registration, product listing and good manufacturing practice only. Every responsible person must report serious adverse events, whatever its size.

Do I report events that happen outside the United States?

Not under MoCRA. The duty covers serious adverse events associated with use of the product in the United States. A reaction in the UK or the EU is assessed under their own serious undesirable effect rules and reported to the authority where it occurred.

Official sources and legislation

S
Written by

Syed Muhammad Shamuel Shees

Founder & Lead Compliance Consultant

Phoenix Safety Consultants is a cosmetic compliance consultancy with offices in London, Tallinn and Pensacola. Our safety assessors and toxicologists prepare CPSRs, Toxicological Risk Assessments, PIFs, SDSs and UK/EU notifications for brands of every size. Talk to the team on WhatsApp or at compliance@phoenixcosmeticsafety.com.

Join the conversation